Infliximab treatment in pachydermoperiostosis: a rare disease without an effective therapeutic option.

Abstract

Hypertrophic osteoarthropathy (HOA) is characterized by periostitis of tubular bones, thickened skin, and digital clubbing. Its pathogenesis is unknown but an inflammatory factor and increased bone remodeling have been implicated. It is a very rare disease, usually diagnosed late with few therapeutic options. Bone and joint pains are secondary to periostitis and are usually difficult to control. Tumor necrosis factor-alpha is a cytokine that induces other inflammatory cytokine production, has an osteoclastogenic effect in different rheumatic diseases and probably also has an important role in periostitis and the systemic inflammatory manifestations in HOA. We describe the case of a patient with the primary form of HOA, who had refractory bone pain and arthritis that responded partially to infliximab treatment.

• Authors: Fernanda Vicente da Costa, Sonia Cristina de Magalhães Souza Fialho, Adriana F Zimmermann, Fabrício S Neves, Gláucio Ricardo Werner de Castro, Ivânio Alves Pereira
• Journal: Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases (J Clin Rheumatol) Vol. 16 Issue 4 Pg. 183-4 (Jun 2010) ISSN: 1536-7355 [Electronic] United States
• PMID: 20414127 (Publication Type: Case Reports, Journal Article)

Chemical References

• Anti-Inflammatory Agents
• Antibodies, Monoclonal
• Tumor Necrosis Factor-alpha
• Infliximab

Topics

• Adult
• Anti-Inflammatory Agents (therapeutic use)
• Antibodies, Monoclonal (therapeutic use)
• Humans
• Infliximab
• Male
• Osteoarthropathy, Primary Hypertrophic (drug therapy)
• Rare Diseases
• Tumor Necrosis Factor-alpha (antagonists & inhibitors)